MK-4827 can inhibit PARP1 and PARP2 with IC50 of 3.8 nM and 2.1 nM. MK-4827 can inhibit PARP activity with EC50 of 4 nM.
In vivo
MK-4827 strongly enhances the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. The enhancement of radiation response is observed in clinically relevant radiation-dose fractionation schedules.